Abstracts
1
University of Southern California, Los Angeles, CA, USA, 2 GlaxoSmithKline, RTP, NC, USA OBJECTIVES: To evaluate 1) use of diabetes and cardiovascular medications; 2) the associations of medication compliance with disease burden. METHODS: California Medicaid administrative data (2002) (2003) (2004) were used to identify patients ≥40 years of age with a diagnosis of type II diabetes concurrent with any combination of the following cardiovascular diseases (CVD): hypertension (HYPT), coronary artery disease (CAD), and heart failure (HF). We assessed patients use of any appropriate diabetes or cardiovascular medication. Proportion of days covered ≥0.8 was used to evaluate medication compliance. Disease burden was defined as any emergency or inpatient visit. Logistic regressions were used to identify factors associated with disease burden in 2004. RESULTS: We identified 21,740 patients. Fifty-six percent of patients filled both diabetes and cardiovascular medications. When compared to patients with comorbid HYPT(51%), those with two CVD conditions HF & CAD(69%) or HYPT & CAD(64%) were more likely to fill both diabetes and cardiovascular medications (P < 0.0001 Prevalence of use for both appropriate diabetes and cardiovascular medications was low in diabetic patients with comorbid CVD. We identified multiple risk factors of disease burden, primarily those related to condition severity (based on proxy measures of comorbidity with two CVD or filling both diabetes and CVD medications), as well as not using or not complying with medications.
PCV12 TRENDS IN C-REACTIVE PROTEIN SCREENING PRIOR TO STATIN USE IN THE UNITED STATES
Slejko JF, Anderson HD, Valuck RJ University of Colorado Denver, Aurora, CO, USA OBJECTIVES: The objective of this study was to explore trends in high sensitivity C-reactive protein (hs-CRP) screening prior to statin use, as compared to current lipid screening practices. METHODS: The PharMetrics Integrated Outcomes Database was used to obtain medical claims records for continuously enrolled adult (≥18 years) first-time statin users. Patients were followed for one year. Both hs-CRP and lipid tests were identified by CPT-4 procedure codes. Descriptive statistics were used to characterize the population and estimate unadjusted associations between patient characteristics and hs-CRP testing. Multivariable logistic regression was used to estimate the odds of testing, controlling for age, gender, diabetes, statin intensity, prescribing physician specialty, geographic region and health plan type. RESULTS: Between July 1, 1997 and March 31, 2007, 33,666 new statin users received lipid tests within 90 days prior to the index statin prescription. One thousand (3%) also received hs-CRP tests during this time. Over 80% of these individuals received the tests in 2004 or later. Those receiving hs-CRP tests were less likely to have a Medicare, Medicaid or other type of plan, as compared to private insurance (P < .05) and were less likely to reside in the South, Midwest or West, as compared to the Northeast (P < 0.01). Individuals who received hs-CRP tests had higher adjusted odds of receiving a high potency statin (OR = 1.37, P < .01) and lower odds of having diabetes (OR = 0.56, P < 0.01). Those receiving hs-CRP tests were more likely to have a cardiologist as their statin-prescribing physician, rather than a family or general practitioner (OR = 1.31, P = 0.02). CONCLUSIONS: Rates of hs-CRP testing are very low, but higher among those seeing a cardiologist or having private insurance. Those who received a high potency statin had higher rates of testing, suggesting that those with higher cardiovascular risk may be more likely to receive an hs-CRP test.
PCV13 THE UTILISATION AND EFFECTIVENESS OF ANTITHROMBOTIC AGENTS FOR PREVENTING DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT-A CASE STUDY IN SOUTHERN TAIWAN
Yu YY 1 , Chen LC 1 , Chien SH 2 1 Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan OBJECTIVES: Antithrombotic therapy is effective in preventing thromboembolic diseases, and it has been recommended by several international guidelines to prevent deep vein thrombosis (DVT) after major orthopedic surgeries under carefully monitoring bleeding risks. To establish Taiwanese local guidance, this case study aims to evaluate the current utilization and effectiveness of antithrombotic agents for preventing DVT after total hip replacement (THR). METHODS: This one-year retrospective cohort study was conducted at a medical center in Southern Taiwan from May 2008 to April 2009. Adult patients (above 18 years) who had undergone primary THR were identified by inpatient electronic database. Their medical records were reviewed from surgery date to three months post-operation for collecting demographic details and DVT-related clinical symptoms as the surrogate of effectiveness. Descriptive statistic and time-to-event analysis were then conducted. RESULTS: Medical records of 82 patients (57.32% women) were reviewed. The average age is 59.15 ± 13.43 years and the mean body mass index is 25.20 ± 4.86 kg/m 2 . Only 31 out of the 82 patients (37.80%) had ever received prophylactic antithrombotic agents after surgery and all of them used aspirin, but only 22 patients used aspirin for more than 10 days. Twelve patients presented DVT symptoms after surgery but only one is from prophylactic group. Independent relative risk of DVT for patients without prophylaxis is 8.25 folds of patients with prophylaxis (95% confidence interval: 1.48, 154.91). DVT symptoms mainly (91.67%) occurred within 15 days after THR and the median duration to symptoms presentation is 12 days. CONCLUSIONS: Antithrombotic therapy is not commonly used to prevent DVT after THR in this medical center. Aspirin alone seems effectively reduces the risk of DVT-related symptoms. It is necessary to further investigate the effectiveness of prophylactic antithrombotic agents after THR from Taiwanese population-based database and explore the potential genetic factors influencing the effectiveness of antithrombotic therapy. each device and the lab was assessed. Agreement was achieved when the INR measures were predicted by a novel, validated method to lead to the same clinical decision. Differences in agreement between the POC devices and the lab were assessed using McNemar's test of paired proportions. RESULTS: Ninetynine subjects were enrolled into the study. There was significantly less difference between INR values from the Coaguchek XS device and the lab compared to the Hemochron device (average absolute difference = 0.24 vs 0.41 p < 0.05). The Hemochron device tended to report both high and low INR values were within the target range when the laboratory said otherwise. Consequently, the Hemochron device was significantly more likely to lead to a different clinical decision than the core laboratory compared to the Coaguchek XS (30% vs. 18%, respectively; RR: 1.7, 95% CI: 1.1-2.4, P = 0.007). CONCLUSIONS: Comparative effectiveness analysis can provide essential information to make informed decisions when selecting medical devices to
PCV14 COMPARATIVE EFFECTIVENESS ANALYSIS IDENTIFIES A SUPERIOR POINT OF CARE DEVICE FOR ASSESSING THE INTERNATIONAL NORMALIZED RATIO

